Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · October 07, 2023

Efficacy, Safety, and Immunogenicity of Biosimilar XSB-001 vs Reference Ranibizumab in Patients With Neovascular AMD

Ophthalmology Retina


Additional Info

Ophthalmology Retina
Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Ophthalmol Retina 2023 Sep 01;7(9)753-761, A Loewenstein, N Czumbel, J Ernest, J Dusová, J Pearlman, A Nowosielska

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading